Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (ucb 44212) at Individualized Doses Up to a Maximum of 160mg/Day in Refractory Epileptic Patients.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Seletracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB Pharma Inc
- 23 Nov 2006 Status change from Initiated to withdrawn prior to recruitment
- 17 Dec 2005 New trial record.